+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Hematuria Treatment Market Forecast to 2033

  • PDF Icon

    Report

  • 100 Pages
  • October 2025
  • Region: Global
  • Grand View Research
  • ID: 6189367
REQUEST CUSTOMIZATION
Description Jump to:
The global hematuria treatment market size was estimated at USD 1.08 billion in 2024 and is projected to reach USD 1.42 billion by 2033, growing at a CAGR of 3.1% from 2025 to 2033. The market is driven by urological care and sustained by the growing prevalence of recurrent urinary tract infections, bladder cancer, and urolithiasis, alongside an expanding geriatric population.

Hematuria is the most common and vital early clinical sign for bladder cancer, which is a high-burden disease that requires extensive diagnostic and therapeutic resources. Moreover, the increasing incidence of bladder cancer cases globally is expected to drive the overall market growth. In the U.S., the American Cancer Society projects 84,870 new cases in 2025, reflecting stable incidence and continued reliance on diagnostic cystoscopy. Given that most bladder cancers require ongoing surveillance through repeated cystoscopy and risk-adapted intravesical therapy, rising case volumes drive the hematuria treatment industry.

Furthermore, rising urinary tract infection (UTI) incidence increases episodic hematuria presentations and empirical antibiotic use, which drives urgent evaluation demand and creates pressure for faster, point-of-care diagnostics. New rapid diagnostics have shortened pathogen identification, directly affecting hematuria treatment pathways by shortening time-to-diagnosis.

Urolithiasis prevalence and symptomatic stone events are important non-neoplastic causes of visible hematuria and often require definitive endourologic care (URS, PCNL) or imaging triage. Although some age-standardised rates have declined, absolute case counts, and new presentations have risen in many regions. It is characterized by symptoms and a high likelihood of recurrence and has created a considerable burden on the healthcare system, especially affecting individuals aged 20 to 54. This indicates substantial age-standardized incidence of stone disease and rising rates in many regions, which raises emergency and elective procedure volumes. Diagnostic cystoscopy remains among the most frequently performed urology procedures, so rising stone and hematuria referrals drive the industry.

Global Hematuria Treatment Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, the analyst has segmented the global hematuria treatment market report based on treatment type, type, and region:

Treatment Type Outlook (Revenue, USD Million, 2021-2033)

  • Pharmacotherapy
  • Procedural / Interventional Therapies
  • Adjunctive / Supportive Therapies

Type Outlook (Revenue, USD Million, 2021-2033)

  • Branded
  • Generic

Regional Outlook (Revenue, USD Million, 2021-2033)

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East & Africa

Why You Should Buy This Report

  • Comprehensive Market Analysis: Gain detailed insights into the market across major regions and segments.
  • Competitive Landscape: Explore the market presence of key players.
  • Future Trends: Discover the pivotal trends and drivers shaping the future of the market.
  • Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions.

Report Deliverables

  • Market intelligence to enable effective decision-making
  • Market estimates and forecasts from 2018 to 2030
  • Growth opportunities and trend analyses
  • Segment and regional revenue forecasts for market assessment
  • Competition strategy and market share analysis
  • Product innovation listings for you to stay ahead of the curve

This product will be delivered within 1-3 business days.

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Treatment type
1.2.2. Type
1.2.3. Regional scope
1.2.4. Estimates and forecasts timeline
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased database
1.4.2. internal database
1.4.3. Secondary sources
1.4.4. Primary research
1.4.5. Details of primary research
1.5. Information or Data Analysis
1.5.1. Data analysis models
1.6. Market Formulation & Validation
1.7. Model Details
1.8. List of Secondary Sources
1.9. List of Primary Sources
1.10. Objectives
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.2.1. Treatment type outlook
2.2.2. Type outlook
2.2.3. Regional outlook
2.3. Competitive Insights
Chapter 3. Hematuria Treatment Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook
3.2. Market Dynamics
3.2.1. Market driver analysis
3.2.2. Market restraint analysis
3.3. Hematuria Treatment Market Analysis Tools
3.3.1. Industry Analysis - Porter’s
3.3.1.1. Supplier power
3.3.1.2. Buyer power
3.3.1.3. Substitution threat
3.3.1.4. Threat of new entrant
3.3.1.5. Competitive rivalry
3.3.2. PESTEL Analysis
3.3.2.1. Political landscape
3.3.2.2. Technological landscape
3.3.2.3. Economic landscape
Chapter 4. Hematuria Treatment Market: Treatment Type Estimates & Trend Analysis
4.1. Treatment Type Segment Dashboard
4.2. Hematuria Treatment Market: Treatment Type Movement Analysis
4.3. Global Hematuria Treatment Market Size & Trend Analysis, by Treatment Type, 2021 to 2033 (USD Million)
4.3.1. Pharmacotherapy
4.3.1.1. Market estimates and forecasts 2021 to 2033 (USD Million)
4.3.2. Procedural / Interventional Therapies
4.3.2.1. Market estimates and forecasts 2021 to 2033 (USD Million)
4.3.3. Adjunctive / Supportive Therapies
4.3.3.1. Market estimates and forecasts 2021 to 2033 (USD Million)
Chapter 5. Hematuria Treatment Market: Type Estimates & Trend Analysis
5.1. Type Segment Dashboard
5.2. Hematuria Treatment Market: Type Movement Analysis
5.3. Global Hematuria Treatment Market Size & Trend Analysis, by Type, 2021 to 2033 (USD Million)
5.3.1. Branded
5.3.1.1. Market estimates and forecasts 2021 to 2033 (USD Million)
5.3.2. Generic
5.3.2.1. Market estimates and forecasts 2021 to 2033 (USD Million)
Chapter 6. Hematuria Treatment Market: Regional Estimates & Trend Analysis
6.1. Regional Market Dashboard
6.2. Regional Market Share Analysis, 2024 & 2030
6.3. Hematuria Treatment Market by Region: Key Takeaways
6.4. North America
6.4.1. U.S.
6.4.1.1. Key country dynamics
6.4.1.2. Regulatory framework/reimbursement structure
6.4.1.3. Competitive scenario
6.4.1.4. U.S. market estimates and forecasts 2021 to 2033 (USD Million)
6.4.2. Canada
6.4.2.1. Key country dynamics
6.4.2.2. Regulatory framework/reimbursement structure
6.4.2.3. Competitive scenario
6.4.2.4. Canada market estimates and forecasts 2021 to 2033 (USD Million)
6.5. Europe
6.5.1. Germany
6.5.1.1. Key country dynamics
6.5.1.2. Regulatory framework/reimbursement structure
6.5.1.3. Competitive scenario
6.5.1.4. Germany market estimates and forecasts 2021 to 2033 (USD Million)
6.5.2. UK
6.5.2.1. Key country dynamics
6.5.2.2. Regulatory framework/reimbursement structure
6.5.2.3. Competitive scenario
6.5.2.4. UK market estimates and forecasts 2021 to 2033 (USD Million)
6.5.3. France
6.5.3.1. Key country dynamics
6.5.3.2. Regulatory framework/reimbursement structure
6.5.3.3. Competitive scenario
6.5.3.4. France market estimates and forecasts 2021 to 2033 (USD Million)
6.5.4. Italy
6.5.4.1. Key country dynamics
6.5.4.2. Regulatory framework/reimbursement structure
6.5.4.3. Competitive scenario
6.5.4.4. Italy market estimates and forecasts 2021 to 2033 (USD Million)
6.5.5. Spain
6.5.5.1. Key country dynamics
6.5.5.2. Regulatory framework/reimbursement structure
6.5.5.3. Competitive scenario
6.5.5.4. Spain market estimates and forecasts 2021 to 2033 (USD Million)
6.5.6. Denmark
6.5.6.1. Key country dynamics
6.5.6.2. Regulatory framework/reimbursement structure
6.5.6.3. Competitive scenario
6.5.6.4. Denmark market estimates and forecasts 2021 to 2033 (USD Million)
6.5.7. Sweden
6.5.7.1. Key country dynamics
6.5.7.2. Regulatory framework/reimbursement structure
6.5.7.3. Competitive scenario
6.5.7.4. Sweden market estimates and forecasts 2021 to 2033 (USD Million)
6.5.8. Norway
6.5.8.1. Key country dynamics
6.5.8.2. Regulatory framework/reimbursement structure
6.5.8.3. Competitive scenario
6.5.8.4. Norway market estimates and forecasts 2021 to 2033 (USD Million)
6.6. Asia-Pacific
6.6.1. Japan
6.6.1.1. Key country dynamics
6.6.1.2. Regulatory framework/reimbursement structure
6.6.1.3. Competitive scenario
6.6.1.4. Japan market estimates and forecasts 2021 to 2033 (USD Million)
6.6.2. China
6.6.2.1. Key country dynamics
6.6.2.2. Regulatory framework/reimbursement structure
6.6.2.3. Competitive scenario
6.6.2.4. China market estimates and forecasts 2021 to 2033 (USD Million)
6.6.3. India
6.6.3.1. Key country dynamics
6.6.3.2. Regulatory framework/reimbursement structure
6.6.3.3. Competitive scenario
6.6.3.4. India market estimates and forecasts 2021 to 2033 (USD Million)
6.6.4. South Korea
6.6.4.1. Key country dynamics
6.6.4.2. Regulatory framework/reimbursement structure
6.6.4.3. Competitive scenario
6.6.4.4. South Korea market estimates and forecasts 2021 to 2033 (USD Million)
6.6.5. Australia
6.6.5.1. Key country dynamics
6.6.5.2. Regulatory framework/reimbursement structure
6.6.5.3. Competitive scenario
6.6.5.4. Australia market estimates and forecasts 2021 to 2033 (USD Million)
6.6.6. Thailand
6.6.6.1. Key country dynamics
6.6.6.2. Regulatory framework/reimbursement structure
6.6.6.3. Competitive scenario
6.6.6.4. Thailand market estimates and forecasts 2021 to 2033 (USD Million)
6.7. Latin America
6.7.1. Brazil
6.7.1.1. Key country dynamics
6.7.1.2. Regulatory framework/reimbursement structure
6.7.1.3. Competitive scenario
6.7.1.4. Brazil market estimates and forecasts 2021 to 2033 (USD Million)
6.7.2. Mexico
6.7.2.1. Key country dynamics
6.7.2.2. Regulatory framework/reimbursement structure
6.7.2.3. Competitive scenario
6.7.2.4. Mexico market estimates and forecasts 2021 to 2033 (USD Million)
6.7.3. Argentina
6.7.3.1. Key country dynamics
6.7.3.2. Regulatory framework/reimbursement structure
6.7.3.3. Competitive scenario
6.7.3.4. Argentina market estimates and forecasts 2021 to 2033 (USD Million)
6.8. MEA
6.8.1. South Africa
6.8.1.1. Key country dynamics
6.8.1.2. Regulatory framework/reimbursement structure
6.8.1.3. Competitive scenario
6.8.1.4. South Africa market estimates and forecasts 2021 to 2033 (USD Million)
6.8.2. Saudi Arabia
6.8.2.1. Key country dynamics
6.8.2.2. Regulatory framework/reimbursement structure
6.8.2.3. Competitive scenario
6.8.2.4. Saudi Arabia market estimates and forecasts 2021 to 2033 (USD Million)
6.8.3. UAE
6.8.3.1. Key country dynamics
6.8.3.2. Regulatory framework/reimbursement structure
6.8.3.3. Competitive scenario
6.8.3.4. UAE market estimates and forecasts 2021 to 2033 (USD Million)
6.8.4. Kuwait
6.8.4.1. Key country dynamics
6.8.4.2. Regulatory framework/reimbursement structure
6.8.4.3. Competitive scenario
6.8.4.4. Kuwait market estimates and forecasts 2021 to 2033 (USD Million)
Chapter 7. Competitive Landscape
7.1. Recent Developments & Impact Analysis, by Key Market Participants
7.2. Company/Competition Categorization
7.3. Vendor Landscape
7.3.1. Key company heat map analysis, 2024
7.4. Company Profiles
7.4.1. AstraZeneca
7.4.1.1. Company overview
7.4.1.2. Financial performance
7.4.1.3. Product benchmarking
7.4.1.4. Strategic initiatives
7.4.2. Bristol-Myers Squibb Company
7.4.2.1. Company overview
7.4.2.2. Financial performance
7.4.2.3. Product benchmarking
7.4.2.4. Strategic initiatives
7.4.3. F. Hoffmann-La Roche Ltd.
7.4.3.1. Company overview
7.4.3.2. Financial performance
7.4.3.3. Product benchmarking
7.4.3.4. Strategic initiatives
7.4.4. Johnson & Johnson and its affiliates
7.4.4.1. Company overview
7.4.4.2. Financial performance
7.4.4.3. Product benchmarking
7.4.4.4. Strategic initiatives
7.4.5. Merck & Co., Inc.
7.4.5.1. Company overview
7.4.5.2. Financial performance
7.4.5.3. Product benchmarking
7.4.5.4. Strategic initiatives
7.4.6. Novartis AG
7.4.6.1. Company overview
7.4.6.2. Financial performance
7.4.6.3. Product benchmarking
7.4.6.4. Strategic initiatives
7.4.7. Pfizer Inc.
7.4.7.1. Company overview
7.4.7.2. Financial performance
7.4.7.3. Product benchmarking
7.4.7.4. Strategic initiatives
7.4.8. Sun Pharmaceutical Industries Ltd.
7.4.8.1. Company overview
7.4.8.2. Financial performance
7.4.8.3. Product benchmarking
7.4.8.4. Strategic initiativesa
List of Tables
Table 1 List of abbreviations
Table 2 Global hematuria treatment market, by region, 2021-2033 (USD Million)
Table 3 Global hematuria treatment market, by treatment type, 2021-2033 (USD Million)
Table 4 Global hematuria treatment market, by type, 2021-2033 (USD Million)
Table 5 North America hematuria treatment market, by country, 2021-2033 (USD Million)
Table 6 North America hematuria treatment market, by treatment type, 2021-2033 (USD Million)
Table 7 North America hematuria treatment market, by type, 2021-2033 (USD Million)
Table 8 U.S. hematuria treatment, by treatment type, 2021-2033 (USD Million)
Table 9 U.S. hematuria treatment market, by type, 2021-2033 (USD Million)
Table 10 Canada hematuria treatment market, by treatment type, 2021-2033 (USD Million)
Table 11 Canada hematuria treatment market, by type, 2021-2033 (USD Million)
Table 12 Europe hematuria treatment market, by country, 2021-2033 (USD Million)
Table 13 Europe hematuria treatment market, by treatment type, 2021-2033 (USD Million)
Table 14 Europe hematuria treatment market, by type, 2021-2033 (USD Million)
Table 15 Germany hematuria treatment market, by treatment type, 2021-2033 (USD Million)
Table 16 Germany hematuria treatment market, by type, 2021-2033 (USD Million)
Table 17 UK hematuria treatment market, by treatment type, 2021-2033 (USD Million)
Table 18 UK hematuria treatment market, by drug, 2021-2033 (USD Million)
Table 19 France hematuria treatment market, by treatment type, 2021-2033 (USD Million)
Table 20 France hematuria treatment market, by type, 2021-2033 (USD Million)
Table 21 Italy hematuria treatment market, by treatment type, 2021-2033 (USD Million)
Table 22 Italy hematuria treatment market, by type, 2021-2033 (USD Million)
Table 23 Spain hematuria treatment market, by treatment type, 2021-2033 (USD Million)
Table 24 Spain hematuria treatment market, by type, 2021-2033 (USD Million)
Table 25 Denmark hematuria treatment market, by treatment type, 2021-2033 (USD Million)
Table 26 Denmark hematuria treatment market, by type, 2021-2033 (USD Million)
Table 27 Sweden hematuria treatment market, by treatment type, 2021-2033 (USD Million)
Table 28 Sweden hematuria treatment market, by type, 2021-2033 (USD Million)
Table 29 Norway hematuria treatment market, by treatment type, 2021-2033 (USD Million)
Table 30 Norway hematuria treatment market, by type, 2021-2033 (USD Million)
Table 31 Asia-Pacific hematuria treatment market, by country, 2021-2033 (USD Million)
Table 32 Asia-Pacific hematuria treatment market, by treatment type, 2021-2033 (USD Million)
Table 33 Asia-Pacific hematuria treatment market, by type, 2021-2033 (USD Million)
Table 34 Japan hematuria treatment market, by treatment type, 2021-2033 (USD Million)
Table 35 Japan hematuria treatment market, by type, 2021-2033 (USD Million)
Table 36 China hematuria treatment market, by treatment type, 2021-2033 (USD Million)
Table 37 China hematuria treatment market, by type, 2021-2033 (USD Million)
Table 38 India hematuria treatment market, by treatment type, 2021-2033 (USD Million)
Table 39 India hematuria treatment market, by type, 2021-2033 (USD Million)
Table 40 South Korea hematuria treatment market, by treatment type, 2021-2033 (USD Million)
Table 41 South Korea hematuria treatment market, by type, 2021-2033 (USD Million)
Table 42 Australia hematuria treatment market, by treatment type, 2021-2033 (USD Million)
Table 43 Australia hematuria treatment market, by type, 2021-2033 (USD Million)
Table 44 Thailand hematuria treatment market, by treatment type, 2021-2033 (USD Million)
Table 45 Thailand hematuria treatment market, by type, 2021-2033 (USD Million)
Table 46 Latin America hematuria treatment market, by country, 2021-2033 (USD Million)
Table 47 Latin America hematuria treatment market, by treatment type, 2021-2033 (USD Million)
Table 48 Latin America hematuria treatment market, by type, 2021-2033 (USD Million)
Table 49 Brazil hematuria treatment market, by treatment type, 2021-2033 (USD Million)
Table 50 Brazil hematuria treatment market, by type, 2021-2033 (USD Million)
Table 51 Mexico hematuria treatment market, by treatment type, 2021-2033 (USD Million)
Table 52 Mexico hematuria treatment market, by type, 2021-2033 (USD Million)
Table 53 Argentina hematuria treatment market, by treatment type, 2021-2033 (USD Million)
Table 54 Argentina hematuria treatment market, by type, 2021-2033 (USD Million)
Table 55 MEA hematuria treatment market, by country, 2021-2033 (USD Million)
Table 56 MEA hematuria treatment market, by treatment type, 2021-2033 (USD Million)
Table 57 MEA hematuria treatment market, by type, 2021-2033 (USD Million)
Table 58 South Africa hematuria treatment market, by treatment type, 2021-2033 (USD Million)
Table 59 South Africa hematuria treatment market, by type, 2021-2033 (USD Million)
Table 60 Saudi Arabia hematuria treatment market, by treatment type, 2021-2033 (USD Million)
Table 61 Saudi Arabia hematuria treatment market, by type, 2021-2033 (USD Million)
Table 62 UAE hematuria treatment market, by treatment type, 2021-2033 (USD Million)
Table 63 UAE hematuria treatment market, by type, 2021-2033 (USD Million)
Table 64 Kuwait hematuria treatment market, by treatment type, 2021-2033 (USD Million)
Table 65 Kuwait hematuria treatment market, by type, 2021-2033 (USD Million)
List of Figures
Figure 1 Market research process
Figure 2 Data triangulation techniques
Figure 3 Primary research pattern
Figure 4 Primary interviews
Figure 5 Market research approaches
Figure 6 QFD modeling for market share assessment
Figure 7 Market formulation & validation
Figure 8 Hematuria treatment market: market outlook
Figure 9 Hematuria treatment competitive insights
Figure 10 Parent market outlook
Figure 11 Related/ancillary market outlook
Figure 12 Penetration and growth prospect mapping
Figure 13 Hematuria treatment market driver impact
Figure 14 Hematuria treatment market restraint impact
Figure 15 Hematuria treatment market strategic initiatives analysis
Figure 16 Hematuria treatment market: treatment type movement analysis
Figure 17 Hematuria treatment market: treatment type outlook and key takeaways
Figure 18 Pharmacotherapy market estimates and forecast, 2021-2033 (USD Million)
Figure 19 Procedural /Interventional therapies market estimates and forecast, 2021-2033 (USD Million)
Figure 20 Adjunctive / Supportive therapies market estimates and forecast, 2021-2033 (USD Million)
Figure 21 Hematuria treatment market: type movement analysis
Figure 22 Hematuria treatment market: type outlook and key takeaways
Figure 23 Branded market estimates and forecasts, 2021-2033 (USD Million)
Figure 24 Generic market estimates and forecasts, 2021-2033 (USD Million)
Figure 25 Global hematuria treatment market: Regional movement analysis
Figure 26 Global hematuria treatment market: Regional outlook and key takeaways
Figure 27 North America market estimates and forecasts, 2021-2033 (USD Million)
Figure 28 U.S. market estimates and forecasts, 2021-2033 (USD Million)
Figure 29 Canada market estimates and forecasts, 2021-2033 (USD Million)
Figure 30 Europe market estimates and forecasts, 2021-2033 (USD Million)
Figure 31 Germany market estimates and forecasts, 2021-2033 (USD Million)
Figure 32 UK market estimates and forecasts, 2021-2033 (USD Million)
Figure 33 France market estimates and forecasts, 2021-2033 (USD Million)
Figure 34 Italy market estimates and forecasts, 2021-2033 (USD Million)
Figure 35 Spain market estimates and forecasts, 2021-2033 (USD Million)
Figure 36 Denmark market estimates and forecasts, 2021-2033 (USD Million)
Figure 37 Sweden market estimates and forecasts, 2021-2033 (USD Million)
Figure 38 Norway market estimates and forecasts, 2021-2033 (USD Million)
Figure 39 Asia-Pacific market estimates and forecasts, 2021-2033 (USD Million)
Figure 40 Japan market estimates and forecasts, 2021-2033 (USD Million)
Figure 41 China market estimates and forecasts, 2021-2033 (USD Million)
Figure 42 India market estimates and forecasts, 2021-2033 (USD Million)
Figure 43 South Korea market estimates and forecasts, 2021-2033 (USD Million)
Figure 44 Australia market estimates and forecasts, 2021-2033 (USD Million)
Figure 45 Thailand market estimates and forecasts, 2021-2033 (USD Million)
Figure 46 Latin America market estimates and forecasts, 2021-2033 (USD Million)
Figure 47 Brazil market estimates and forecasts, 2021-2033 (USD Million)
Figure 48 Mexico market estimates and forecasts, 2021-2033 (USD Million)
Figure 49 Argentina market estimates and forecasts, 2021-2033 (USD Million)
Figure 50 Middle East and Africa market estimates and forecasts, 2021-2033 (USD Million)
Figure 51 South Africa market estimates and forecasts, 2021-2033 (USD Million)
Figure 52 Saudi Arabia market estimates and forecasts, 2021-2033 (USD Million)
Figure 53 UAE market estimates and forecasts, 2021-2033 (USD Million)
Figure 54 Kuwait market estimates and forecasts, 2021-2033 (USD Million)

Companies Mentioned

The companies profiled in this Hematuria Treatment market report include:
  • AstraZeneca
  • Bristol-Myers Squibb Company
  • F. Hoffmann-La Roche Ltd.
  • Johnson & Johnson and its affiliates
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • Sun Pharmaceutical Industries Ltd.

Table Information

Report AttributeDetails
No. of Pages100
PublishedOctober 2025
Forecast Period2024 - 2033
Estimated Market Value ( USD ) in 2024 $ 1.08 Billion
Forecasted Market Value ( USD ) by 2033 $ 1.42 Billion
Compound Annual Growth Rate3.1%
Regions CoveredGlobal
No. of Companies Mentioned9

Related Topics

Related Reports

Hematuria - Market Insight, Epidemiology and Market Forecast - 2034 - Product Image

Hematuria - Market Insight, Epidemiology and Market Forecast - 2034

  • Report
  • 200 Pages
  • Global
From
Genitourinary Drugs Market Report by Indication, Product, and Region 2025-2033 - Product Image

Genitourinary Drugs Market Report by Indication, Product, and Region 2025-2033

  • Report
  • 146 Pages
  • Global
From
Hematuria Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034 - Product Image

Hematuria Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

  • Report
  • 133 Pages
  • Global
From
Hematuria - Pipeline Insight, 2025 - Product Image

Hematuria - Pipeline Insight, 2025

  • Drug Pipelines
  • 60 Pages
  • Global
From
Genitourinary Drugs Market Size, Share & Trends Analysis Report By Indication (Prostate, Ovarian, Bladder, Cervical Cancer, UTI & STD), By Product (Hormonal Therapy, Gynecological), By Region, And Segment Forecasts, 2023 - 2030 - Product Image

Genitourinary Drugs Market Size, Share & Trends Analysis Report By Indication (Prostate, Ovarian, Bladder, Cervical Cancer, UTI & STD), By Product (Hormonal Therapy, Gynecological), By Region, And Segment Forecasts, 2023 - 2030

  • Report
  • 110 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.